-
Sector Analysis
Sepsis Therapeutics Market Size, Share & Trends Analysis and Forecast 2021 – 2030
The global sepsis market has been valued at $3.48 billion in 2020 and is expected to grow at a CAGR of more than 7.5% across the seven major pharmaceutical markets (7MM) the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan during the forecast period. As of 2020, the market has been dominated by antibiotics and supportive therapies for the treatment of sepsis, most of which are available as generic versions. Due to its high diagnosed incidence rate...
-
Sector Analysis
Respiratory Syncytial Virus Prophylaxis – Global Drug Forecast and Market Analysis to 2030
Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. RSV infection generally causes mild flu-like symptoms, which can include a runny nose, lowered appetite, fever, coughing, and/or sneezing. Irritability and difficulty breathing may be the only symptoms shown by very young infants with RSV. RSV is a viral infection that is transmitted through contact with droplets in the air or on surfaces like doorknobs, tabletops,...
-
Sector Analysis
PharmaPoint: Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2025
Neisseria meningitidis is a Gram-negative, encapsulated diplococcal bacterium and is the causative agent for invasive meningococcal disease. Although relatively rare around the globe, invasive meningococcal disease is widely feared because of its high mortality rate even in otherwise healthy individuals. The onset of invasive meningococcal disease typically begins within three to seven days of infection, but can occur as early as one day after infection. If left untreated, meningococcal disease progresses rapidly. Even with appropriate treatment, up to 10% of...
-
Sector Analysis
Pediatric Combination Vaccines - Global Drug Forecast and Market Analysis to 2028
Well-organized immunization schedules for infants, children, and adolescents are the cornerstone of public health campaigns in most developed and developing countries. In particular, vaccines are the most effective method of protecting the general population and select groups of people against infectious diseases. In the US alone, childhood vaccines are estimated to prevent 14 million infections, avoid 33,000 premature deaths annually, and save $43bn in direct and indirect costs for each fully vaccinated US birth cohort. Across the nine major pharmaceutical...
-
Sector Analysis
Nontuberculous Mycobacteria (NTM) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
The NTM market size in the US, the UK, and Japan was $8.59 billion in 2021 and is expected to achieve a CAGR of more than 2% during 2021-2031. The NTM market will grow as the diagnosed prevalent cases of nontuberculous mycobacteria (NTM) infections are expected to increase in the US, the UK, and Japan between 2021 and 2031. The NTM market research report provides an analysis of the key dynamics of the NTM drugs market. The report also offers...
-
Sector Analysis
Pneumococcal Vaccines - Global Drug Forecast and Market Analysis to 2028
Streptococcus pneumoniae (S. pneumoniae), a Gram-positive bacterial respiratory pathogen, is a leading cause of mortality and morbidity globally and is responsible for a large proportion of deaths due to infectious disease. In 2005, The World Health Organization (WHO) estimated 1.6 million deaths were caused by S. pneumoniae annually, including 0.7-1 million children under the age of 5 years. In Europe and the US, the annual incidence of pneumococcal disease ranges from 10 to 100 per 100,000 population. S. pneumoniae causes...
-
Sector Analysis
Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2029
Meningococcal disease is an infection caused by Neisseria meningitidis bacteria, and, although relatively rare, is widely feared because of its high mortality rate even in otherwise healthy individuals. Serogroups A, B, C, W, and Y are the most common meningococcal types in the nine major markets (9MM) covered in this report (US, France, Germany, Italy, Spain, UK, Argentina, Brazil, and China), and immunization of high-risk groups such as infants and adolescents provides the best protection against the infection. Immunization with...
-
Sector Analysis
Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2028
Seasonal influenza is a viral infection that occurs annually in the winter months from December to March/April in the Northern Hemisphere and from May to August/September in the Southern Hemisphere. Two types of influenza virus, type A and B, are responsible for the majority of seasonal influenza infections in humans, and due to frequent virus mutations annual vaccination is recommended. The WHO estimates three to five million cases of severe seasonal influenza infections and 290,000 to 650,000 influenza-related respiratory deaths,...
-
Sector Analysis
PharmaPoint: Hepatitis C Virus (HCV) Therapeutics – Global Drug Forecast and Market Analysis to 2025
The hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), HCC, and eventually death. A member of the Flaviviridae viral family and hepacivirus genus, HCV can be classified into six major genotypes, with many additional subtypes within each genotype. While genotype 1 (GT1) causes almost half of HCV infections, all six major genotypes (GT1-6) are prevalent worldwide. The...
-
Sector Analysis
PharmaPoint: Seasonal Influenza Vaccines – Global Drug Forecast and Market Analysis to 2025
Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection's rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza. Today, available vaccines include the older egg-based,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.